There have been several biomarkers that have been looked at and tested, and then, with time and studies, really two biomarkers have come about that are now almost routinely used, I would say, in GvHD and definitely commercially available, and this is Sd2 and REG-3-alpha. They are primarily biomarkers of gastrointestinal involvement and we know that really gastrointestinal involvement kind of has the most impact on the severity of GvHD...
There have been several biomarkers that have been looked at and tested, and then, with time and studies, really two biomarkers have come about that are now almost routinely used, I would say, in GvHD and definitely commercially available, and this is Sd2 and REG-3-alpha. They are primarily biomarkers of gastrointestinal involvement and we know that really gastrointestinal involvement kind of has the most impact on the severity of GvHD. And then these two biomarkers can be combined into one value that then we can use as a probability of risk of developing GvHD. It has been developed through MAGIC consortium. And then this probability, this risk is called MAP, which is magic algorithm probability. It is really more sensitive and specific than clinical symptoms in predicting the ability of responding to treatment, but also the risk of developing GvHD. When this was, for example, tested even on day seven before- after transplant, before any sign of acute GvHD, and it can prevent the risk of severe acute GvHD prior to onset of any clinical symptoms.
